6 things you need to know about Bladder Cancer | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Bladder cancer

June 2018

6 things you need to know about Bladder Cancer

  • Bladder cancer is the ninth most commonly diagnosed cancer in the world with an estimated 430 000 new cases reported in 2012.
  • Men are more than three times more likely to get bladder cancer than women.
  • Smoking is a major cause of bladder cancer.
  • Exposure to industrial chemicals such as metalworking fluids is another cause of bladder cancer.
  • One of the most common symptoms of bladder cancer is the presence of blood in urine.
  • Cystoscopy and urine cytology are the most common methods for detection and assessment of recurrence of bladder cancer. Cystoscopy may cause pain and discomfort in patients, and urine cytology has a low sensitivity.IDL Biotech has developed UBC Rapid, a complement to cystoscopy, which causes no pain for the patient. Read more about UBC Rapid here.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.

IDL Biotech

Skip this intro